IBAB cites strong H1 growth and reaffirms EBIT guidance
IBAB says H1 growth and profitability were driven by Proton Therapy, reaffirming its EBIT guidance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.